No Data
No Data
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) adding 0.3%. The iShares Biotechnology ETF (IBB) rose
Sector Update: Health Care
Health care stocks were advancing late Thursday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) adding 0.3%. The iShares Biotechnology ETF (IBB) ro
Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com
By Bill Alpert Weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, have launched a market that analysts expect will grow to $100 billion in 10 years. Drug developers from those fir
Form 144 | Eli Lilly and Co(LLY.US) 10% Stockholder Proposes to Sell 191.66 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 20, $Eli Lilly and Co(LLY.US)$ 10% Stockholder LILLY ENDOWMENT INC intends to sell 215K shares of its common stock on Jun 20, with a total market value of approximately $19
Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update
By David Wainer Gilead Sciences, a biotech company focused on treatments for cancer and HIV, isn't pitching itself as an obesity-drug developer. But that hasn't stopped some Wall Street analysts from
No Data